Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


Proprietary MiDROPS™ technology is also available to formulate small lipohilic molecules for topical instillation (eyedrop).  This patented technology platform can deliver test agents to both the anterior and posterior segments of the eye.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Once-daily MiDROPS™ are superior to other Cyclosporine drops dosed 2x/day and provide faster therapeutic benefit to patients

"Ophthalmic distribution studies indicate significantly increased drug concentration with … Read More

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 EyeCRO and MPI Research, … Read More

Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy

"Diabetic retinopathy is a leading cause of vision loss. Previous studies have shown signaling … Read More

More News

Sunday, November 18th, 2018 at 3:21pm
Blind Dog Was Scared To Walk. So Owner Made This For Him https://t.co/foEiPKWSVv
Friday, November 16th, 2018 at 6:44am
@megtirrell Looking forward to your segment on gene therapy today! As scientists we agree with this fundamental principal. Durability of expression to maintain therapeutic levels is more important that achieving higher drug levels that do not confer any additional patient benefit https://t.co/mxZIA1CqFp
Preclinical Ophthalmic Contract Research